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no. ISTN3X; 96% identical), com-
prising one of Tn3-like inverted
repeats and putative coding regions
for transposase, resolvase (also called
repressor), and ampicillin resistance.
The resistance gene encodes a TEM-1
type β-lactamase. (The sequence has
been registered to DDBJ/GenBank/
EMBLwith accession no. AB103092.) 
Conjugative transferability of
p981123 between S. Enteritidis strains
was examined by using the parental S.
Enteritidis RDNC-a R-AS strain as a
donor, and three independent S.
Enteritidis strains (PT1; PT4; and
PT21) resistant to nalidixic acid (R-
N) as recipients. p981123 was trans-
ferable between S. Enteritidis strains
at frequencies of 10-5 to 10-4, and the
resulting R-AN transconjugant
showed the same lytic pattern of the
typing phages as RDNC-a. Thus,
transfer of p981123 could convert the
phage types at least from PT1, PT4,
and PT21 to RDNC-a. Pulsed-field
gel electrophoresis (PFGE) was done
by using XbaI or BlnI as well, and
RDNC-a strains showed a variety of
PFGE profiles. These results suggest
emergence and prevalence of the 50-
kb R-plasmid converting phage types
to RDNC-a in S. Enteritidis in Japan.
Previous studies reported correla-
tion between R-plasmids and phage
types of S. Enteritidis, where, for
example, a 34-MDa R-plasmid of
incompatibility group N (IncN) (8)
and a 36-MDa R-plasmid of IncX
(pDEP57) (6) were described. Both
kinds of plasmids encoded ampicillin
resistance as well as that in this study,
but both were identified in PT6a iso-
lates. Preliminary sequence data of
the region of p981123 essential for
replication indicated a gene coding
for a protein similar to protein p1 of
R6K (IncX) plasmid (9), which sug-
gests that p981123 may be related to
pDEP57. However, the reactions to
the typing phages in RDNC-a strains
were different from those in PT6a.
Therefore, the R-plasmid in this study
seems to have different features from
previous ones. In addition, S.
Enteritidis PT6d resistant to ampi-
cillin was recently reported (10).
Relationship between RDNC-a in this
study and PT6d is unknown, and fur-
ther investigations will be needed.
Transfer of an R-plasmid is a com-
mon way for bacteria to acquire drug
resistance, and it often affects other
aspects such as sensitivity of bacterio-
phages, as described in this study.
Molecular based surveillance for drug
resistance in S. Enteritidis needs to
continue.
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Factors Influencing
Fluoroquinolone
Resistance 
To the Editor: Recently, Scheld
summarized factors that he consid-
ered to have an influence on the effi-
cacy of fluoroquinolones (1). In the
review, ciprofloxacin was presented
as the most active fluoroquinolone
against  Pseudomonas aeruginosa
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with MICs typically two- to eightfold
lower than those for levofloxacin,
moxifloxacin, or gatifloxacin.
However, because the National
Committee for Clinical Laboratory
Standards (NCCLS) MIC interpreta-
tive breakpoints are fluoroquinolone-
specific, percent susceptibility is con-
sidered to be a better measure by
which to compare fluoroquinolone
activities. Our company has conduc-
ted annual investigations called
TRUST (Tracking Resistance in the
United States Today) since 1996.
These surveillance studies have con-
sistently shown similar susceptibility
rates for levofloxacin (67.7% in 2002)
and ciprofloxacin (67.4% in 2002)
against  P. aeruginosa (2,3). Both
agents show higher in vitro activity
against  P. aeruginosa than gati-
floxacin and moxifloxacin (2–4). A
critique of antipseudomonal fluoro-
quinolone activity should also con-
sider peak achievable fluoroquinolone
levels at a site of infection, the area
under the serum concentration curve
in 24 hours (AUC24h), and the
AUC24h/MIC ratio (5). At equivalent
dosages for nosocomial pneumonia,
levofloxacin (750 mg intravenously,
once daily) has a threefold higher
peak serum level (Cmax) and threefold
higher AUC24h than ciprofloxacin
(400 mg intravenously, every 8 hours)
(package inserts for Levaquin and
Cipro). While certain P. aeruginosa
isolates have lower ciprofloxacin than
levofloxacin MICs, the two fluoro-
quinolones have equivalent activity
against P. aeruginosa because of their
equivalent AUC24h /MIC ratios (6).
We agree strongly with Scheld’s sug-
gestion that the fluoroquinolone used
clinically should be the fluoro-
quinolone tested by the laboratory and
reported; surrogate testing of fluoro-
quinolones may lead to major errors
in reporting, particularly for
Enterobacteriaceae (2,3,7).
The review also stated that lev-
ofloxacin-resistant strains of P. aerug-
inosa emerge at a significantly higher
rate than with ciprofloxacin.
However, a recent study of P. aerugi-
nosa isolated from cystic fibrosis
patients reported that fewer resistant
mutants were isolated after exposure
to levofloxacin (11 mutants) than to
ciprofloxacin (28 mutants) (8).
With regards to S. pneumoniae, the
review stated that in vitro studies have
demonstrated that ciprofloxacin (1–4
mg/L) and levofloxacin (1–2 mg/L)
are not as active as moxifloxacin
(0.06–0.25 mg/L) and gatifloxacin
(0.5–1 mg/L) against pneumococci.
As with P. aeruginosa, fluoro-
quinolone comparisons against S.
pneumoniae should not be limited to
MICs alone because pharmacokinetic
and pharmacodynamic characteristics
differ for each fluoroquinolone.
Pneumococcal time-kill studies with
levofloxacin, gatifloxacin, and moxi-
floxacin in a pharmacodynamic
model have demonstrated that these
three agents possess equal bacterici-
dal activity and are equally effective
in preventing resistance development
because the lower in vitro MICs for
gatifloxacin and moxifloxacin were
offset by the higher serum and tissue
levels of levofloxacin (9). In the same
study, ciprofloxacin did not exhibit
rapid killing and selected for resist-
ance faster than the other three agents
(9). TRUST and other U.S. surveil-
lance studies, using the NCCLS-rec-
ommended broth-dilution method,
have shown that S. pneumoniae
remain highly susceptible to lev-
ofloxacin with resistance rates in the
United States of <1%; the MIC90 for
levofloxacin in these studies has
remained at 1 mg/L from 1997
through 2002 (10–15). Further, lev-
ofloxacin, gatifloxacin, and moxi-
floxacin are equally effective in rates
of clinical cure and microbiologic
eradication of pneumococcal respira-
tory infections (16, and FDA website;
available from: URL: http://www.fda.
gov/cder/foi/nda/99/21061_Tequin.ht
m and http://www.fda.gov/cder/foi/
nda/2001/21277_Avelox.htm)
The review implied that, in gener-
al, higher AUC24h/MIC ratios were
associated with better patient out-
comes. For S. pneumoniae, several
pharmacodynamic studies have
demonstrated that a target
AUC24h/MIC ratio of 30 to 35 for flu-
oroquinolones is the best correlate for
successful bacteriologic eradication,
clinical cure, and prevention of emer-
gence of resistance during therapy
(5,9,17–19). Levofloxacin, gati-
floxacin, and moxifloxacin all achieve
this AUC24h/MIC ratio (9). Zhanel et
al. demonstrated that AUC24h/MIC
ratios above the target value of 30 to
35 did not improve bacteriologic
eradication or reduce the emergence
of resistance (9). Moreover, no clini-
cal data support the claim that higher
AUC24h/MIC ratios correlate with bet-
ter patient outcomes.
The review discusses the question
of whether C-8-methoxyquinolones
(moxifloxacin and gatifloxacin) have
a lower propensity to select resistant
mutants of S. pneumoniae compared
with levofloxacin. Mutation preven-
tion concentration is a theoretical lab-
oratory concept based on agar dilution
methodology, and no published data
have shown any clinical correlation
between this theory and clinical out-
comes. NCCLS does not recommend
agar dilution for susceptibility analy-
sis of S. pneumoniae. Moreover, the
extremely low levels of resistance in
S. pneumoniae (<1%) after many
years of fluoroquinolone use do not
support the theory of mutation pre-
vention concentration. The review did
not reference an analysis of 16 peni-
cillin-resistant S. pneumoniae strains
by Kolhepp et al. (20). In that broth-
dilution study, in vitro resistance
developed in a greater proportion of
strains exposed to gatifloxacin (11/16)
and moxifloxacin (8/16) than to lev-
ofloxacin (2/16). Similarly, in a study
by Klepser et al. that used an in vitro
pharmacodynamic model, lev-
ofloxacin was less likely than moxi-
floxacin to select for resistant isolates
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of S. pneumoniae; moreover, after 24
hours of exposure, levofloxacin MICs
remained unchanged while moxi-
floxacin MICs increased two- to
eightfold (21).
Levofloxacin, gatifloxacin, and
moxifloxacin all have susceptibility
rates >99% for S. pneumoniae
(22,23). Although resistance is rare,
considerable cross-resistance among
fluoroquinolones is observed once
two or more key mutations (e.g., Ser79
in ParC, Ser81 in GyrA) are detected
(24,25). Using topoisomerase IV-
selecting fluoroquinolones (ciproflo-
xacin and levofloxacin) in the same
patient population as DNA gyrase-
selecting fluoroquinolones (gati-
floxacin and moxifloxacin) could
potentially accelerate the develop-
ment of double mutants (ParC and
GyrA) and clinically important class
resistance because selective pressure
would be applied to both enzyme tar-
gets (26).
The review stated that, since 1999,
at least 20 case reports of pulmonary
infection that did not respond to lev-
ofloxacin therapy have been pub-
lished. This number is remarkably
small considering that >250 million
patients have been treated with lev-
ofloxacin worldwide. Anumber of the
treatment failures cited had documen-
tation of prior ciprofloxacin use and
ciprofloxacin failure, and many iso-
lates were not tested for levofloxacin
susceptibility before treatment (27).
We agree with the recommendation in
the cited Davidson et al. reference: a
patient’s failure to respond to one flu-
oroquinolone is sufficient reason not
to use other fluoroquinolones (27).
Isolated clinical failures will occur
with the use of any antimicrobial
agent when treating pneumococcal
pneumonia.
The notion that fluoroquinolone
therapy can be “targeted” for an indi-
cation requires challenge as fluoro-
quinolone therapy will always result
in systemic drug levels. Evidence
does not indicate that the use of two
fluoroquinolones, such as ciproflo-
xacin and moxifloxacin, minimizes
fluoroquinolone resistance. Targeted
fluoroquinolone therapy may in fact
have adverse implications for the
patient and for overall institutional
resistance patterns. For example, the
use of ciprofloxacin for urinary tract
infections exposes resident strepto-
cocci in the respiratory tract to an
agent that has demonstrated weaker
activity against pneumococci, thus
potentially selecting for pneumococ-
cal resistance (9). Moreover, 20%-
35% of ciprofloxacin is excreted
through the intestinal tract (Cipro
package insert), compared to 4% of
levofloxacin (Levaquin package
insert). Studies have shown that
ciprofloxacin displays weaker in vitro
activity (lower percentage of isolates
susceptible) than levofloxacin for sev-
eral gram-negative enteric bacteria
(2,3). Stepwise adaptive changes
towards fluoroquinolone resistance in
enteric bacteria may be selected by
fluoroquinolones with weaker in vitro
activity and higher levels of exposure
in the intestinal tract. Therefore,
ciprofloxacin would have a greater
potential than levofloxacin for the
selection of resistant strains of intes-
tinal gram-negative pathogens. A
recent report stated that ciprofloxacin-
resistant Escherichia coli were isolat-
ed from the feces of 48% of patients
treated with ciprofloxacin for prostati-
tis; before ciprofloxacin therapy, only
ciprofloxacin-susceptible E. coli were
isolated from the feces of these
patients (28). Further, given that 25%
of moxifloxacin is excreted through
the intestinal tract (Avelox package
insert), the use of moxifloxacin for
respiratory infections exposes bac-
teria in the intestinal tract to a fluoro-
quinolone with greater activity
against Bacteroides fragilis and other
intestinal anaerobes than levofloxacin
(29,30). Moxifloxacin has a greater
potential than other fluoroquinolones
to alter the normal intestinal flora and
select for vancomycin-resistant ente-
rococci (31) and intestinal gram-nega-
tive strains with increased fluoro-
quinolone resistance.
In conclusion, we believe that the
data we have briefly presented here
supplements the previous discussion
by Scheld (1) and will help facilitate
an improved understanding of the fac-
tors influencing the maintenance of
fluoroquinolone efficacy. 
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International 
Travel and Sexually
Transmitted
Disease 
To the Editor: Recent articles in
the professional literature (1–3) have
offered advice regarding the impor-
tance of taking a careful travel history,
particularly in this time of unprece-
dented levels of international travel
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